A Study of LY3041658 in Adults With Hidradenitis Suppurativa

I7P-MC-DSAD -

The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).

Trial Summary

Age Range
18 - 65 years
Conditions the trial is for
Hidradenitis Suppurative (Acne Inversa)
What the trial is testing?
LY3041658
Could I receive a Placebo?
Yes
Enrollment Goal
72
Trial Dates
Aug 26, 2020 - Oct 13, 2022
How long will I be in the trial?
The study will last about 46 weeks and may include up to 22 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have a diagnosis of HS for at least 6 months

  • Participants must have HS lesions in at least 2 different anatomic areas

  • Participants must have inadequate response or intolerance to a 28 day course of oral antibiotics

  • Participants must have a total count of abscesses and inflammatory nodules greater than or equal to 4

  • Participants must agree to use a topical antiseptic daily

  • Participants must agree to stop using topical antibiotics during the study. In certain cases, oral antibiotics will be allowed

Participants Must Not:

  • Participants must not have more than 20 draining fistulae

  • Participants must not have received any biologic medication (adalimumab, etc.) for the treatment of HS

  • Participants must not plan to use oral opioids for HS-related pain during the study

  • Participants must not have uncontrolled depression or suicidal thoughts

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources